Table 1.
Clinical and polysomnographic characteristics of patients with narcolepsy type 1 (NT1) and rapid eye movement sleep behavior disorder (RBD), and of patients with idiopathic RBD (iRBD).
| Variable | NT1 with RBD N = 34 | iRBD N = 15 | |||
|---|---|---|---|---|---|
| n | % | n | % | p-value | |
| Clinical characteristics | |||||
| Sex (Male) | 25 | 73.53 | 12 | 80.00 | 0.73 |
| Age at evaluation, yearsa | 51.00 (15.00; 86.00) | 72.00 (48.00; 82.00) | 0.0002 | ||
| BMI, kg/m2a | 26.52 (17.00; 47.80) | 25.40 (22.28; 33.80) | 0.19 | ||
| BMI, kg/m2 (≥30) | 8 | 23.53 | 2 | 13.33 | 0.70 |
| Cardiovascular and metabolic comorbiditiesb (yes) | 20 | 58.82 | 10 | 66.67 | 0.60 |
| Age of RBD onset, yearsa | 36.00 (15.00; 65.00) | 62.00 (47.00; 76.00) | <0.0001 | ||
| RBD duration, yearsa | 9.50 (0.50; 40.00) | 6.00 (1.00; 15.00) | 0.65 | ||
| Daily RBD episodes (yes) | 7 | 20.6 | 5 | 33.33 | 0.34 |
| NT1 duration, yearsa | 17.00 (0.50; 69.00) | — | |||
| Nocturnal sleep characteristics | |||||
| Total Sleep Time, minutesa | 369.50 (164.00; 522.00) | 381.00 (229.00; 445.00) | 0.81 | ||
| Night Sleep Latency, minutesa | 5.00 (0.00; 38.00) | 31.00 (4.00; 106.00) | <0.0001 | ||
| Night REM Sleep Latency, minutesa | 55.00 (0.00; 328.00) | 119.00 (35.00; 234.00) | 0.03 | ||
| Sleep efficiency, %a | 77.81 (35.61; 95.55) | 76.87 (50.90; 93.00) | 0.65 | ||
| % Stage 1a | 11.06 (2.52; 31.70) | 7.99 (1.56; 16.25) | 0.04 | ||
| % Stage 2a | 47.68 (32.80; 78.05) | 57.54 (32.89; 67.09) | 0.17 | ||
| % Stage 3a | 14.93 (0.00; 38.19) | 12.04 (0.85; 38.99) | 0.95 | ||
| % REM sleepa | 22.78 (1.81; 37.62) | 20.05 (3.11; 30.89) | 0.48 | ||
| AHI /houra | 6.65 (0.00; 59.39) | 10.21 (0.00; 37.77) | 0.78 | ||
| PLMS index, /houra | 8.52 (0.20; 161.89) | 5.00 (0.00; 154.28) | 0.47 | ||
| Micro-arousal index, /houra | 21.95 (3.30; 68.57) | 21.71 (2.23; 37.69) | 0.92 | ||
| Mean Oxygen Saturation %a | 95.00 (87.00; 97.00) | 94.00 (91.00; 96.00) | 0.51 | ||
| REM sleep without atonia | |||||
| Phasic EMG activity %a | 9.15 (1.50; 31.67) | 20.60 (2.86; 67.80) | 0.006 | ||
| Phasic EMG activity % (≥15%) | 9 | 26.47 | 12 | 80 | 0.002 |
| Tonic EMG activity %a | 19.15 (0.70; 96.43) | 38.57 (1.25; 95.00) | 0.02 | ||
| Tonic EMG activity (≥30%) | 10 | 29.41 | 9 | 60 | 0.18 |
| Phasic (≥15%) or Tonic (≥30%) EMG activities | 12 | 35.29 | 12 | 80 | 0.01 |
aContinuous variables are expressed as median (minimal value; maximal value).
REM = rapid eye movement, BMI = body mass index, AHI = apnea hypopnea index, PLMS = periodic leg movement during sleep, EMG = electromyography, MSLT = multiple sleep latency test, SOREMPs = sleep onset REM periods.
bCardiovascular and metabolic comorbidities: Presence of diabetes type 2 or use of antidiabetic drugs, cardiac disorders (personal history of coronary artery disease, chronic heart failure, arrhythmia), hypertension or treatment with antihypertensive drugs, dyslipidemia or treatment with lipid-lowering drugs, or stroke.